The brokerage cautioned that despite the recent decline, valuations remain high, indicating potential further downside unless policy interventions offer relief. Nuvama favored exporters like chemicals ...

Strides Pharma Science is well on track to achieve the FY25 outlook of $275 million-$290 million, post-demerger.

Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after 12 years in management at Japan's biggest drugmaker. Julie Kim, president of the company's U.S. unit, was named to ...